Evaluation of Long-Term Safety of ADYNOVI/ADYNOVATE (Antihaemophilic Factor [Recombinant] PEGylated, Rurioctocog Alfa Pegol) in Participants With Haemophilia A - An ADYNOVI/ADYNOVATE Post-Authorisation Safety Study (PASS)
Condition: Hemophilia A Intervention: Biological: ADYNOVI/ADYNOVATE Sponsors: Baxalta now part of Shire; Baxalta Innovations GmbH, now part of Shire; Shire is now part of Takeda Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials